Table 1 Patient characteristics
All patients | PD | LBD | MSA | PSP | CBD | Others | |
|---|---|---|---|---|---|---|---|
N | 62 | 20 | 22 | 6 | 5 | 1 | 8 |
Male/female | 25/37 | 10/10 | 8/14 | 2/4 | 3/2 | 0/1 | 2/6 |
Age at diagnosis (y), mean +/− SD | 64 +/− 13.4 | 56.7 +/− 16.2 | 69.8 +/− 9.3 | 60.7 +/− 4.5 | 64 +/− 9.7 | 70 | 68.2 +/− 14.9 |
Disease duration (mo), mean +/− SD | 66 +/− 45 | 81.6 +/− 59.8 | 53.7 +/− 33.1 | 66.5 +/− 15.8 | 58.4 +/− 60.2 | 38 | 68.7 +/− 32.3 |
Duration of symptoms before scintigraphy (mo), mean +/− SD | 47.3 +/− 43.4 | 65.8 +/− 59.9 | 35.3 +/− 25.7 | 47.7 +/− 19.5 | 48.8 +/− 57 | 28 | 35.3 +/− 29.7 |
AR/T/ART/Non motor | 32/5/22/3 | 6/3/11/0 | 12/1/8/1 | 6/0/0/0 | 3/0/2/0 | 1/0/0/0 | 4/1/1/2 |
H&Y, mean +/− SD | 2.4 +/− 1.2 | 2.4 +/− 1.2 | 2.3 +/− 1.1 | 3.6 +/− 1.2 | 3 +/− 0 | 4 | 1 +/− 1.1 |
L-Dopa-equivalent dose, mean +/− SD, (N) | 407.5 +/− 436.9 (37) | 520 +/− 438.2 (16) | 260 +/− 374.6 (10) | 638.3 +/− 502.4 (5) | 840 +/− 378.2 (4) | 0 (0) | 139.5 +/− 262.9 (2) |
DaTSCAN, N | 40 | 11 | 14 | 5 | 3 | 1 | 6 |
Neuropsychological assessment, N | 50 | 12 | 21 | 4 | 4 | 1 | 8 |